Home›Research›Compare›GLP-2 vs Larazotide
Peptide ComparisonGLP-2 vs Larazotide
Both are Tissue Repair peptides.
GLP-2
Glucagon-like Peptide-2
11 providers listed
Larazotide
AT1001
Half-life: ~30 minutes (local gut action)
11 providers listed
GLP-2 is FDA-approved, while Larazotide is investigational — the clearest structural difference between them.
GLP-2
Evidence
Half-life
—
Larazotide
Evidence
Half-life
~30 minutes (local gut action)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | GLP-2 |
| Further along in FDA review | GLP-2 |
| Oral administration option | Larazotide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
GLP-2
Larazotide
GLP-2
Prostaglandin E2 stimulates GLP-1 and GLP-2 secretion and reduces glucose absorption in the perfused rat smal…
The Role of Vasoactive Intestinal Peptide in Glucagon-like Peptide-2-Mediated Intestinal Lipid Handling.
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowe…
+4 more
Larazotide
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized control…
Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stre…
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during glu…
About GLP-2
Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.
About Larazotide
Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
GLP-2
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Larazotide
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
GLP-2
Larazotide
Not enough vendor pricing yet.
Where to source these peptides
GLP-2
11 listed
Browse directory →
Providers offeringLarazotide
11 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). GLP-2 vs Larazotide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/glp-2/larazotide